このエントリーをはてなブックマークに追加
ID 61142
著者
Haruki, Yuto Department of Pharmacy, Tsuyama Chuo Hospital
Hagiya, Hideharu Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
Haruki, Mai Department of Pharmacy, Tsuyama Chuo Hospital
Inoue, Yuta Department of Pharmacy, Tsuyama Chuo Hospital
Sugiyama, Tetsuhiro Department of Pharmacy, Tsuyama Chuo Hospital
抄録
Introduction
Recent studies have corroborated that the co-administration of vancomycin (VCM) and piperacillin/tazobactam (PT) is correlated with an increased incidence of acute kidney injury (AKI). However, evidence directed at the Japanese population is scarce. Therefore, we conducted a retrospective study to compare the occurrence of AKI among Japanese patients who received VCM with PT (VP therapy) and VCM with another β-lactams (VA therapy).
Methods
The present study, performed at Tsuyama Chuo Hospital between June 2012 and December 2018, included adult patients who received VCM and β-lactam antibiotics for ≥48 h. We defined the primary outcome as the incidence of AKI based on the risk, injury, failure, loss, and end-stage kidney disease criteria. Patients' clinical characteristics and outcomes were reviewed and compared between the two groups with univariate and multivariate logistic regression analyses. Subgroup analysis was conducted by stratifying the patients’ baseline hospital admittance status, as intensive care unit or general wards.
Results
We analyzed 272 patients (92 V P therapy and 180 VA therapy). Univariate analysis revealed a significant difference in AKI development between VP and VA therapy (25.0% vs 12.2%; p < 0.01). A multivariate analysis demonstrated that VP therapy and VCM initial trough levels ≥15 μg/mL were associated with an incidence of AKI. Patients at general wards, rather than those admitted at an intensive care unit, developed AKI with VP therapy (p = 0.02).
Conclusion
VP therapy was associated with an increased risk of AKI compared to that with VA therapy among the Japanese population.
キーワード
Acute kidney injury
β-lactams
Piperacillin/tazobactam
Vancomycin
備考
This fulltext is available in Oct. 2021.
発行日
2020-10
出版物タイトル
Journal of Infection and Chemotherapy
26巻
10号
出版者
Elsevier
開始ページ
1026
終了ページ
1032
ISSN
1341-321X
NCID
AA11057978
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
author
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1016/j.jiac.2020.05.012
ライセンス
https://creativecommons.org/licenses/by-nc-nd/4.0/